Aptevo Therapeutics Inc.
APVO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $3,114 | $12,292 |
| % Growth | – | -100% | -74.7% | – |
| Cost of Goods Sold | $352 | $0 | $0 | $0 |
| Gross Profit | -$352 | $0 | $3,114 | $12,292 |
| % Margin | – | – | 100% | 100% |
| R&D Expenses | $14,378 | $17,107 | $17,882 | $18,994 |
| G&A Expenses | $10,224 | $11,771 | $13,873 | $14,698 |
| SG&A Expenses | $10,224 | $11,771 | $13,873 | $14,698 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$352 | $0 | $0 | $0 |
| Operating Expenses | $24,250 | $28,878 | $31,755 | $33,692 |
| Operating Income | -$24,602 | -$28,878 | -$28,641 | -$21,400 |
| % Margin | – | – | -919.7% | -174.1% |
| Other Income/Exp. Net | $472 | $10,228 | $35,655 | -$8,008 |
| Pre-Tax Income | -$24,130 | -$18,650 | $7,014 | -$29,408 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$24,130 | -$17,411 | $8,027 | -$28,457 |
| % Margin | – | – | 257.8% | -231.5% |
| EPS | -1,747.68 | -46,335 | 51,243 | -197,647 |
| % Growth | 96.2% | -190.4% | 125.9% | – |
| EPS Diluted | -1,747.68 | -46,335 | 51,217 | -197,647 |
| Weighted Avg Shares Out | 14 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 14 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $352 | $567 | $901 | $1,144 |
| EBITDA | -$23,778 | -$28,311 | -$27,740 | -$20,256 |
| % Margin | – | – | -890.8% | -164.8% |